COPENHAGEN, Aug 12 (Reuters) - Denmark's Genmab announced positive results from a Phase II study of Arzerra (ofatumumab) to treat chronic lymphocytic leukaemia (CLL) in previously untreated patients.
Arzerra, which is being co-developed by GlaxoSmithKline, was given in combination with fludarabine and cyclophosphamide (FC) to 61 patients.
The overall response rate was 77 percent in a 500 mg treatment group and 73 percent in a 1000...
Researchers from Spain affiliated with the TASMAN clinical trial have reported that maintenance Taxol (paclitaxel) administered after induction with Taxol and Ellence (epirubicin) does not improve progression-free survival. The details of this study were presented at the 2009 meeting of the American Society of Clinical Oncology in May/June.[1]
The role of maintenance therapy in women with metastatic breast cancer is unresolved. Over the past one or...
* Recommended as first-line treatment for common leukaemia
* To be used with fludarabine and cyclophosphamide
* Not recommended in combination with other chemo agents
LONDON, July 22 (Reuters) - British drugs agency NICE has recommended Roche's (ROG.VX) top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukaemia.
The National Institute for Health and Clinical Excellence...
Genetic Variant Associated with Resistance to Chemotherapy Drug in Women with Breast Cancer
Embargoed for Release
Tuesday, June 9, 2009
1:00 p.m., EDT
National Institutes of Health
Researchers have found links between an individual’s genetics and their response to treatment with chemotherapy. The findings, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, show how a genetic...
START Trial Will Show Whether Therapeutic Vaccine Stimuvax Has Potential To Extend Lung Cancer Survival Beyond Five Years
Article Date: 01 Jun 2009 - 4:00 PDT
Of all cancers, non-small cell lung cancer (NSCLC) represents one of the greatest unmet needs for an effective and life-prolonging treatment. The condition, which accounts for 85 per cent of all lung cancers - roughly 1.4 million worldwide each year - is rarely diagnosed at its earliest and most potentially curable...
